| Autor: |
Dua, Isha, Tan, Antoinette R. |
| Předmět: |
|
| Zdroj: |
American Journal of Hematology/Oncology; May2017, Vol. 13 Issue 5, p20-27, 8p |
| Abstrakt: |
Triple-negative breast cancer (TNBC) is a clinically heterogeneous and molecularly diverse disease. At present, chemotherapy is the standard treatment for early-stage and metastatic TNBC. The paucity of actionable targets, lack of targeted therapies, and relatively poor prognosis of patients with TNBC have created ample opportunity to evaluate novel treatment approaches. An improved understanding of the immunogenicity of TNBC has led to clinical studies of several immunotherapeutic agents. Early phase I trials with immune checkpoint inhibitors in TNBC report an overall response rate of up to 19% with durable clinical responses and a tolerable safety profile. The hope is that immunotherapy strategies will provide new therapeutic options for TNBC. This review focuses on the emerging data about immune checkpoint inhibitors in the treatment of TNBC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
